10-Q: Koru Medical Systems Reports Q1 2026 Growth

Koru Medical Systems Inc. announced a 22.1% increase in net revenues for Q1 2026, driven by strong performance in its core domestic and international businesses, alongside significant growth in its pharma services segment.

Summary

• Koru Medical Systems reported Q1 2026 net revenues of $11.8 million, a 22.1% increase year-over-year.
• Domestic core revenues grew 11.7% to $7.7 million, and international core revenues increased 35.2% to $3.3 million.
• Pharma services and clinical trials revenue surged by 166.0% to $0.7 million.
• Gross profit rose by 19.6% to $7.2 million, though gross margin slightly decreased to 61.5% from 62.8% in the prior year.
• Operating expenses increased by 11.0% to $8.1 million, primarily due to higher selling, general, and administrative (SG&A) and research and development (R&D) costs.
• The company reported a net loss of $0.8 million for the quarter, an improvement from a net loss of $1.2 million in Q1 2025.
• Cash and cash equivalents stood at $8.8 million as of March 31, 2026.
• The company amended its loan and security agreement, extending the maturity of its revolving credit facility and term loan, and lowering the interest rate floor.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive report, with strong revenue growth and a narrowing net loss, but tempered by a slight decrease in gross margin and continued operational expenses.

Positives

• Net revenues increased by 22.1% to $11.8 million in Q1 2026 compared to Q1 2025.
• Domestic core revenue growth of 11.7% driven by higher consumable volumes and market share gains.
• International core revenue growth of 35.2% driven by higher pump and consumable volumes.
• Pharma services and clinical trials revenue experienced substantial growth of 166.0%.
• Gross profit increased by 19.6% to $7.2 million.
• Net loss decreased by 30.8% to $0.8 million in Q1 2026 from $1.2 million in Q1 2025.
• The company's credit facility was amended to extend maturities and lower interest rate floors, providing greater financial flexibility.

Negatives

• Gross margin decreased to 61.5% from 62.8% in the prior year period, attributed to higher production costs and tariff-related charges.
• Operating expenses increased by 11.0% to $8.1 million, driven by higher SG&A and R&D costs.
• The company continues to report a net loss, although it has narrowed.
• Inventory increased by $0.8 million to $4.5 million, reflecting expected future demand but also tying up capital.

Risks

• Uncertainties associated with inflation, tariffs, war, and geopolitical conflicts.
• Fluctuations in customer ordering patterns.
• Availability and costs of raw materials and labor, and the ability to recover such costs.
• Regulatory compliance with the FDA and foreign authorities, and the outcome of regulatory audits.
• Introduction and adoption of competitive products.
• Market acceptance of new and existing products.
• Ability to penetrate new markets.
• Success in enforcing and obtaining patents.
• Reimbursement related risks.
• Government regulation of the home health care industry.
• Success of research and development efforts.
• Demand in the SCIg market.
• Availability of sufficient capital if or when needed.
• Dependence on key personnel.
• Potential impact of global supply imbalances on financial markets.
• Uncertainty regarding the amount and timing of potential refunds for tariffs paid.

Future Outlook

The company expects its current cash on hand, cash flows from operations, and available credit facility to be sufficient to meet its requirements for at least the next twelve months. However, continued execution on its strategic plan may necessitate drawing on the credit facility, taking on additional debt, or raising capital through equity issuance. Future capital requirements are subject to various factors including sales growth rate, R&D spending, international expansion, new product introductions, market acceptance, and economic conditions.

Management Comments

• The Company ended the first quarter of 2026 with $11.8 million in net revenues, a 22.1% increase compared to $9.6 million in the same period last year.
• Revenues were driven by growth in our core domestic and international business of 11.7% and 35.2%, respectively, along with an increase of 166.0% in our pharma services and clinical trials business.
• Gross profit for the first quarter of 2026 was $7.2 million, a 19.6% increase compared to $6.0 million in the same period last year, primarily driven by volume growth.
• Gross margin was 61.5% for the three months ended March 31, 2026, a decrease from 62.8% in the prior year period.
• Operating expenses for the first quarter of 2026 were $8.1 million, compared to $7.3 million for the same period last year, driven by an increase of $0.6 million in selling, general, and administrative expenses, and an increase of $0.2 million in research and development expenses.
• Our net loss decreased $0.4 million in the three months ended March 31, 2026, as compared to the prior year period, primarily driven by an increase in gross profit of $1.2 million, driven by increased revenues, partially offset by operating expense increases of $0.8 million.

Industry Context

StockSavvy.ai notes that Koru Medical Systems' Q1 2026 results reflect a growing demand in the subcutaneous drug delivery market, particularly for immunoglobulin therapies. The significant increase in pharma services and clinical trials revenue suggests the company is successfully leveraging its platform for drug development support, a trend observed across the broader medical device and biopharmaceutical sectors.

Comparison to Industry Standards

• The company's gross margin of 61.5% is strong for a medical device manufacturer, though slightly below the prior year's 62.8%. Industry benchmarks for gross margins in this sector can vary widely, but margins in the high 50s to low 70s are often seen for companies with proprietary technology and specialized products.
• The 22.1% year-over-year revenue growth is robust, especially for a company in a niche market. Competitors in the broader drug delivery device market may show varying growth rates depending on their product lifecycle and market penetration. For instance, companies focused on high-volume, generic drug delivery might see slower growth compared to Koru's specialized subcutaneous infusion solutions.
• The continued net loss, while narrowing, is not uncommon for companies investing heavily in R&D and market expansion, a strategy often employed by smaller, growth-oriented medical technology firms aiming to capture market share.

Management Changes

Legal Proceedings

• The Company is not presently a party to any litigation or other legal proceedings that is believed to be material to its financial condition.

Stakeholder Impact

• Shareholders: The company's continued growth and narrowing net loss may be viewed positively, but the ongoing net loss and potential need for future capital raises could impact share value.
• Employees: Increased R&D and SG&A expenses suggest continued investment in personnel and operations, potentially leading to growth opportunities.
• Customers: The company's focus on core domestic and international markets, along with pharma services, indicates a commitment to serving its customer base.
• Suppliers: Increased inventory levels suggest sustained demand, which could benefit suppliers.
• Creditors: The amendment to the credit facility provides greater financial flexibility, which could be seen as positive by creditors.

Next Steps

• Continue to invest in research and development.
• Support future growth through inventory management.
• Potentially draw on the credit facility or seek additional financing if needed for future business activities and expansion.
• Monitor and manage the impact of tariffs and global economic conditions.
• CEO Linda Tharby to transition to a non-executive advisory role on June 30, 2026, and remain on the Board through December 31, 2026.

Key Dates

Recommendation

Koru Medical Systems demonstrates strong revenue growth and improved profitability metrics, indicating positive operational momentum. However, the company continues to operate at a net loss, and future capital needs remain a consideration. The recent amendment to the credit facility offers some financial flexibility. Given the mixed signals of growth alongside ongoing losses and potential financing needs, a 'hold' recommendation is prudent for seasoned investors, suggesting a wait-and-see approach to monitor the path to profitability and the impact of strategic investments.

Keywords

Koru Medical Systems, Form 10-Q, Quarterly Report, Medical Devices, Subcutaneous Infusion, Drug Delivery, Revenue Growth, Net Loss, Financial Results, Pharma Services, Clinical Trials, FDA Regulations, Credit Facility Amendment